With the increasing number, complexity, and diversity of biomarkers to be tested in support of precision medicine approaches, limited tissue availability and patient health status can be barriers to genomic testing. Liquid biopsies provide an alternative to invasive tissue sample collection to match patients with appropriate therapies based on their genomic profile. In this presentation, Roos will discuss the rationale and drivers for the implementation of a CGP liquid biopsy assay to better support molecular testing and therapy matching. She will also highlight real-world evidence that demonstrates the clinical utility of including liquid biopsies in biomarker testing algorithms in both academic and community oncology practices.
Alison Roos, PhD
Associate Director Medical Affairs, Illumina
Your email address is never shared with third parties.